OKYO Pharma LTD
June 18, 2025
Company Presentation
Ophthalmology
153C
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial.
Company HQ City:
New York
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Urcosimod
CEO
Gary Jacob
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
Exchange
Nasdaq
Ticker
OKYO
When you expect your next catalyst update?
Phase 2 data readout of trial of urcosimod for the treatment of neuropathic corneal pain
What is your next catalyst (value inflection) update?
Q3 2025
Website
www.okyopharma.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}